(-0.05%) 5 476.00 points
(-0.08%) 38 787 points
(-0.02%) 19 918 points
(0.29%) $80.56
(1.18%) $2.82
(0.24%) $2 334.60
(-0.17%) $29.34
(-0.21%) $968.90
(0.02%) $0.932
(-0.14%) $10.64
(0.06%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A...
Stats | |
---|---|
Šios dienos apimtis | 81 878 |
Vidutinė apimtis | 120 683 |
Rinkos kapitalizacija | 56.22M |
EPS | $-3.00 ( Q2 | 2023-08-07 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.515 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $1.161 (5.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-11 | Flagship Ventures Fund V General Partner Llc | Sell | 113 960 | Common Stock |
2023-08-11 | Eli Lilly & Co | Buy | 1 718 493 | Common Stock |
2023-08-11 | Cole Douglas G. | Sell | 683 | Stock Option (Right to Buy) |
2023-08-11 | Cole Douglas G. | Sell | 683 | Stock Option (Right to Buy) |
2023-08-11 | Oesterle Stephen N. | Sell | 683 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
68.97 |
Last 96 transactions |
Buy: 15 034 169 | Sell: 5 311 777 |
Tūris Koreliacija
Sigilon Therapeutics, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
DICE | 0.802 |
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Sigilon Therapeutics, Koreliacija - Valiuta/Žaliavos
Sigilon Therapeutics, Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $12.94M |
Bruto pelnas: | $12.94M (100.00 %) |
EPS: | $-1.340 |
FY | 2022 |
Pajamos: | $12.94M |
Bruto pelnas: | $12.94M (100.00 %) |
EPS: | $-1.340 |
FY | 2021 |
Pajamos: | $9.60M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.43 |
FY | 2020 |
Pajamos: | $13.37M |
Bruto pelnas: | $13 374.00 (0.10 %) |
EPS: | $-7.55 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Sigilon Therapeutics,
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.